RobertJFallonMD

Oncology • Indianapolis, IN

Director, section of Pediatric Hematology-Oncology

Join to view full profile

Dr. Fallon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Fallon's full profile

Already have an account?

Office
705 Riley Hospital Dr
Roc 4340
Indianapolis, IN 46202
Phone+1 317-944-5611

Fax+1 317-944-3107
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1984 - 1986
Brigham & Womens Hosp1980 - 1986
New York University School of MedicineClass of 1980

Certifications & Licensure

IN State Medical License 2000 - 2019

Clinical Trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25
Recruiting
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Start of enrollment: 2008 Feb 04
Active, not recruiting
Phase 3
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma Start of enrollment: 2008 Feb 04
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Start of enrollment: 2011 Sep 01
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor Start of enrollment: 2011 Aug 01
Completed
Phase 2
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant Start of enrollment: 2013 Mar 21
Completed
Phase 3
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission Start of enrollment: 2012 Feb 21
Active, not recruiting
Phase 3
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors Start of enrollment: 2012 Jun 27
Active, not recruiting
Phase 2
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2013 Feb 12
Completed
Phase 2
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas Start of enrollment: 2013 Jun 17
Active, not recruiting
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia Start of enrollment: 2013 Jun 24
Completed
Phase 2
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. Start of enrollment: 2013 Aug 20
Completed
Phase 2
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Start of enrollment: 2013 Nov 13
Active, not recruiting
Phase 2
Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma Start of enrollment: 2013 Dec 24
Completed
Phase 2
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma Start of enrollment: 2014 Aug 01
Completed
Phase 2
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Start of enrollment: 2014 Oct 04
Active, not recruiting
Phase 3
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
Join now to see all

Publications & Presentations

PubMed

SUCCESSFUL TREATMENT OF A SOLITARY SKULL METASTASIS IN A CHILD WITH WILMS' TUMOR.
Lucas A McDuffie, Robert Fallon, Terry A. Vik, Deborah F. Billmire> ;Journal of Pediatric Surgery Case Reports. 2017 Jul 1
23 citations
Reduction in Overt and Silent Stroke Recurrence Rate Following Cerebral Revascularization Surgery in Children with Sickle Cell Disease and Severe Cerebral Vasculopathy.
Erin M. Hall, Jeffrey R. Leonard, Jodi L. Smith, Kristin P. Guilliams, Michael M. Binkley, Robert J. Fallon, Monica L. Hulbert> ;Pediatric Blood & Cancer. 2016 Aug 1
57 citations
Risk-prediction tool for identifying hospitalized children with a predisposition for development of venous thromboembolism: Peds-Clot clinical Decision Rule.
Anjali Sharathkumar, Arash Mahajerin, L. Heidt, K. Doerfer, Mark E. Heiny, Terry A. Vik, Robert Fallon, Alfred Rademaker> ;Journal of Thrombosis and Haemostasis. 2012 Jul 1
24 citations
Clinical course of postthrombotic syndrome in children with history of venous thromboembolism.
Susan Creary, Mark E. Heiny, James M. Croop, Robert Fallon, Terry A. Vik, Monica L. Hulbert, Holly M. Knoderer, Manjusha Kumar, Anjali Sharathkumar> ;Blood Coagulation & Fibrinolysis. 2012 Jan 1
93 citations
Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study o...
Monica L. Hulbert, Douglas J. Scothorn, Julie A. Panepinto, J. Paul Scott, George R. Buchanan, Sharada A. Sarnaik, Robert J. Fallon, Jen Yih Chu, Winfred C. Wang, Jame...> ;The Journal of Pediatrics. 2006 Nov 1
44 citations
Long-term outcomes in patients with stage IV neuroblastoma
Mauricio A. Escobar, Jay L. Grosfeld, Robert L. Powell, Karen W. West, L.R. Scherer, Robert Fallon, Frederick J. Rescorla> ;Journal of Pediatric Surgery. 2006 Feb 1
35 citations
Heterologous cells cooperate to augment stem cell migration, homing, and engraftment.
Gregor B. Adams, Karissa T. Chabner, Russell B. Foxall, Kathryn W. Weibrecht, Neil P. Rodrigues, David Dombkowski, Robert Fallon, Mark C. Poznansky, David T. Scadden> ;Blood. 2003 Jan 1
30 citations
Esthesioneuroblastoma in children.
Manjusha Kumar, Robert Fallon, James S. Hill, Mary M. Davis> ;Journal of Pediatric Hematology/oncology. 2002 Aug 1
170 citations
Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke.
Douglas J. Scothorn, Cynthia L. Price, Daniel Schwartz, Cindy Terrill, George R. Buchanan, Wanda Shurney, Ingrid Sarniak, Robert J. Fallon, Jen Yih Chu, Charles H. Peg...> ;The Journal of Pediatrics. 2002 Mar 1
2 citations
c-src tyrosine kinase is associated with the asialoglycoprotein receptor in human hepatoma cells.
Amy Parker, Robert Fallon> ;Molecular Cell Biology Research Communications. 2001 Nov 1
126 citations
CXCR-4 Desensitization Is Associated with Tissue Localization of Hemopoietic Progenitor Cells
Hongmei Shen, Tao Cheng, Ivona T. Olszak, Eduardo A. Garcia-Zepeda, Zhijian Lu, Steven H. Herrmann, Robert Fallon, Andrew D. Luster, David T. Scadden> ;Journal of Immunology. 2001 Apr 15
8 citations
Deletion of 3'-CBFB gene in association with an inversion (16)(p13q22) and a loss of the Y chromosome in a 2-year-Old child with acute myelogenous leukemia-M4.
Jacqueline R. Batanian, Yufeng Huang, Robert Fallon> ;Cancer Genetics and Cytogenetics. 2000 Sep 1
10 citations
T-lymphopoietic capacity of cord blood-derived CD34+ progenitor cells.
J. P. Gardner, Michael Rosenzweig, D. F. Marks, D. Harper, K. Gaynor, Robert Fallon, D. A. Wall, R P Johnson, David T. Scadden> ;Experimental Hematology. 1998 Sep 1
20 citations
The asialoglycoprotein receptor is associated with a tyrosine kinase in HepG2 cells.
Robert Fallon, Maria Danaher, Amit Saxena> ;The Journal of Biological Chemistry. 1994 Oct 28
40 citations
Bile acid efflux mediated by the rat liver canalicular bile acid transport/ecto-ATPase protein requires serine 503 phosphorylation and is regulated by tyrosine 488 pho...
C J Sippel, Robert J. Fallon, David H. Perlmutter> ;The Journal of Biological Chemistry. 1994 Jul 29
24 citations
Expression of an endogenous asialoglycoprotein receptor in a human intestinal epithelial cell line, Caco-2
Jian Zhao Mu, Robert J. Fallon, Paul E. Swanson, Shirley Carroll, Maria Danaher, David H. Alpers> ;Biochimica Et Biophysica Acta. 1994 Jul 21
34 citations
Defective asialoglycoprotein receptor endocytosis mediated by tyrosine kinase inhibitors. Requirement for a tyrosine in the receptor internalization signal.
Robert J. Fallon, Maria Danaher, Robert L. Saylors, Amit Saxena> ;The Journal of Biological Chemistry. 1994 Apr 15
17 citations
The effect of staurosporine, a protein kinase inhibitor, on asialoglycoprotein receptor endocytosis
Robert J. Fallon, Maria Danaher> ;Experimental Cell Research. 1992 Dec 1
61 citations
The serpin-enzyme complex (SEC) receptor mediates the neutrophil chemotactic effect of alpha-1 antitrypsin-elastase complexes and amyloid-beta peptide.
Gregg Joslin, Gail L. Griffin, Anna M. August, S P Adams, Robert J. Fallon, Robert M. Senior, David H. Perlmutter> ;The Journal of Clinical Investigation. 1992 Sep 1
85 citations
Amyloid-beta peptide, substance P, and bombesin bind to the serpin-enzyme complex receptor.
Gregg Joslin, James E. Krause, Andrew D. Hershey, S P Adams, Robert J. Fallon, David H. Perlmutter> ;The Journal of Biological Chemistry. 1991 Nov 15
87 citations
The SEC receptor recognizes a pentapeptide neodomain of alpha 1-antitrypsin-protease complexes.
Gregg Joslin, Robert J. Fallon, Joseph Bullock, Steven Paul Adams, David H. Perlmutter> ;The Journal of Biological Chemistry. 1991 Jun 15
29 citations
A pool of intracellular phosphorylated asialoglycoprotein receptors which is not involved in endocytosis.
Willem Stoorvogel, Alan L. Schwartz, Ger J. Strous, Robert J. Fallon> ;The Journal of Biological Chemistry. 1991 Mar 25
6 citations
Low concentrations of primaquine inhibit degradation but not receptor-mediated endocytosis of asialoorosomucoid by HepG2 cells.
John S. Reif, Alan L. Schwartz, Robert J. Fallon> ;Experimental Cell Research. 1991 Feb 1
98 citations
Endocytosis and degradation of alpha 1-antitrypsin-protease complexes is mediated by the serpin-enzyme complex (SEC) receptor.
David H. Perlmutter, Gregg Joslin, Patricia Nelson, Chuck Schasteen, S P Adams, Robert J. Fallon> ;The Journal of Biological Chemistry. 1990 Oct 5
54 citations
Staurosporine inhibits a tyrosine protein kinase in human hepatoma cell membranes
Robert J. Fallon> ;Biochemical and Biophysical Research Communications. 1990 Aug 16
Join now to see all

Hospital Affiliations

Indiana University Health University HospitalIndianapolis, Indiana
Indiana University Health North HospitalCarmel, Indiana

RobertJFallonMD

Dr. Fallon is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.